JSJoseph R. Scalea

Joseph R. Scalea

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joseph R. Scalea has a total of 249 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • SETI—The Semi-Elective Transplant Initiative

    by Christof Kaltenmeier, Steven I. Hanish, Santosh Nagaraju, Tara Barry, Eric D. Bolin, Patrick J. Cawley, Pravin Meenashi Sundaram, Tom Crawford, Kannan Samy, Diego Di Sabato, et al.

    Objective: To evaluate whether formal integration of preservation strategy with predictable operating room access was associated with measurable changes in transplant timing, preservation practice, the logistical profile of transplanted grafts, and early clinical outcomes. Summary Background Data: Deceased donor kidney transplantation remains a reactive process requiring urgent mobilization of hospital resources. As volumes increase and hospitals operate near capacity, this creates operational barriers that limit organ utilization. We report a retrospective evaluation of a prospectively implemented operational redesign; the design does not support causal inference. Methods: Adult deceased-donor kidney transplants (January 2022–June 2025) were grouped into pre-SETI, SETI-1 (expanded machine perfusion), and SETI-2 (morning operating room access). A contemporaneous SRTR cohort (N=12,302) served as the comparator. Results: Among 936 transplants, mean cold ischemia time (CIT) increased after SETI (20.2→21.9 h, P =0.0039). Donation after circulatory death (DCD) kidneys with CIT >30 hours increased from 0.5% pre-SETI to 7.7% after full implementation ( P P P =0.071) or graft failure (5.4→3.2%, P =0.34); these comparisons were underpowered and do not establish equivalence. Donor hypertension predicted graft failure, whereas CIT, DCD status, and SETI era did not. Conclusions: Systems-based operational redesign transformed reactive deceased-donor kidney transplantation into a proactive model, enabling transplantation of a greater proportion of logistics-sensitive grafts, including DCD kidneys and organs with prolonged CIT, within existing healthcare resources. Whether this increases net organ utilization was not established by these data.

  • Open Access

    Innovations in Organ Delivery: A Comparative Review

    by Jaimeen K. Shah, Joseph R. Scalea

    Purpose of Review: This review examines recent innovations in organ delivery across three domains: organ preservation and ex vivo perfusion, digital and predictive transport infrastructure, and physical delivery vectors including advanced air mobility and unmanned aerial vehicles (UAVs), summarizing the current evidence and maturity differences across each domain. Recent Findings: Extended ex vivo perfusion and normothermic regional perfusion have lengthened viable transport windows and improved graft function. Artificial intelligence and real-time telemetry tools for allocation and logistics show growing interest but remain early-stage. UAV-based delivery has progressed from isolated demonstrations to systematic feasibility analysis, though substantial regulatory barriers remain. Summary: No single innovation outperforms the others; each addresses a different point along the transport chain. Preservation extends available time, digital tools inform its use, and physical transport determines delivery speed and reliability. Comparative-effectiveness research and infrastructure investment are needed before any approach is clearly preferred.

  • A Two‐Center Randomized Controlled Trial to Assess Financial Incentives for Compliance With Living Kidney Donor Follow‐Up in the United States

    by Shivani S. Bisen, Tanveen Ishaque, Alvin G. Thomas, Madeleine M. Waldram, Daniel S. Warren, Jaclyn Bannon, Joseph R. Scalea, Dorry L. Segev, Jacqueline M. Garonzik‐Wang, Allan B. Massie, et al.

    Introduction: The United States Organ Procurement and Transplantation Network mandates collection of 6‐month, 1‐year, and 2‐year post‐donation follow‐up data on living kidney donors (LKDs), but many centers struggle to meet these requirements. This study investigated whether providing a financial incentive (mailed gift card) could increase patient compliance with LKD follow‐up. Methods: A parallel, non‐blinded, 1:1 superiority randomized control trial of LKDs was conducted at two centers from March 2017 to February 2021. The control arm received standard of care (SOC): instructions to complete the mandated LKD follow‐up consisting of a health questionnaire and laboratory measurements at 6 months, 1 year, and 2 years post‐donation. The intervention arm received SOC and was mailed a $25 gift card for each timely completed follow‐up. Compliance rates were compared at each timepoint using Poisson regression. Results: A total of 175 donors consented to participate. The 6‐month, 1‐year, and 2‐year follow‐up compliance rates were 65.2%, 63%, and 65.2% in the control arm, and 71.1%, 60.2%, and 53.0% in the intervention arm, respectively. No statistically significant improvement in compliance was observed with the gift card intervention (IRR = 0.89 1.09 1.34 at 6 months, 0.76 0.96 1.21 at 1 year, and 0.63 0.81 1.05 at 2 years). Similarly, no differences were observed in compliance with clinical follow‐up, laboratory follow‐up, or individual questions or lab values. Conclusion: Mailed gift cards did not improve patient compliance with LKD follow‐up requirements; such interventions may be counterproductive among LKDs. Further research is needed to investigate and address barriers to completing LKD follow‐up. Trial Registration: ClinicalTrials.gov identifier: NCT03090646


  • Four Reasons to Live

    by Joseph R. Scalea

  • Myeloid-Derived Suppressor Cells for Achieving Transplant Tolerance: Preclinical Testing of CD84+/MerTK+ Myeloid-Derived Suppressor Cells to Control Alloreactivity

    by Fei Qiao, Dirk Van Der Windt, Tom Morinelli, Yuan Zhai, Joseph Scalea

    Myeloid-derived suppressor cells are a naturally occurring, heterogenous group of regulatory cells that are expanded in times of inflammation and can control anti-donor T-cell responses. We sought to clarify which of these heterogenous phenotypes control anti-donor responses and whether CD84 and MerTK may better define a subset of these cells that may best control anti-donor T-cell responses for the purposes of transplantation. We used T-cell proliferation and co-culture assays to assess function of myeloid-derived suppressor cells across a complete major histocompatibility complex mismatch. We used flow cytometry to assess phenotypes of these cells and CD4 T cells. Granulocyte colony-stimulating factor-expanded myeloid-derived suppressor cells expressed CD84 and MerTK. Among these cells, 9% to 20% were CD84+/MerTK+. MerTK knockout of these cells showed 75% reduction in suppression of T-cell proliferation in co-culture assays versus wild-type cells. Likewise, myeloid-derived suppressor cells from CD84 knockout animals also demonstrated a 70% reduction in suppression of T-cell proliferation. CD84 expression was nearly eliminated (99%) in MerTK knockout animals. To model simultaneous elimination of CD84 and MerTK, we used anti-CD84 blocking antibody in wild-type and MerTK knockout cells. Blocking CD84 among MerTK knockout cells eliminated suppression of T-cell proliferation. In purified CD84+/MerTK+ myeloid-derived suppressor cells, complete elimina-tion of T-cell proliferation was observed. CD84+ and MerTK+ appear to be required for the suppression of T cells in co-culture assays. Because granulocyte colony-stimulating factor-expanded myeloid-derived suppressor cells were shown in the same model to induce tolerance, CD84+/MerTK+ cells may represent a so-called "ideal" myeloid-derived suppressor cell for tolerance or immunosuppression minimization. Thoughtful operational strategies may allow successful clinical protocols that exploit the suppressive nature of CD84+/MerTK+ myeloid-derived suppressor cells. Future work with human cell lines and clinical studies is required to better understand the role of this important cell type in transplant patients.

  • Open Access

    Initial exploration of a novel fusion protein, IL-4/IL-34/IL-10, which promotes cardiac allograft survival mice through alloregulation

    by Young S. Lee, I-Ting Cheng, Godoy-Ruiz Raquel, David J. Weber, Joseph R. Scalea

    Immune mediated graft loss still represents a major risk to transplant recipients. Creative approaches to immunosuppression that exploit the recipient's own alloregulatory mechanisms could reduce the need for pharmacologic immunosuppression and potentially induce immune tolerance. In the process of studying recipient derived myeloid derived suppressor cells (MDSCs), we identified key alloregulatory MDSC mechanisms, mediated by isolatable proteins IL-4, IL-34, and IL-10. We sought to purify these proteins and fuse them for subsequent infusion into transplant recipients as a means of inducing an alloregulatory response. In this introductory investigation, we leveraged molecular engineering technology to create a fusion protein (FP) of three cytokine coding sequences of IL-4, IL-34, and IL-10 and demonstrated their expressions by Western Blot analysis. Following purification, we tested whether FP IL-4/IL-34/IL-10 (FP1) can protect heart transplant allografts. Injection of FP1 significantly prolonged allogeneic cardiac graft survival in a dose-dependent fashion and the increase of graft survival time exceeded survival attributable to IL-34 alone. In vitro, MDSCs cells were expanded by FP1 treatment. However, FP1 did not directly inhibit T cell proliferation in vitro. In conclusion, newly developed FP1 improves the graft survival in cardiac transplantation mouse model. Significant additional work to optimize FP1 or include other novel proteins could supplement current treatment options for transplant patients.


  • Simultaneous Pancreas and Kidney Transplantation

    by Wen Xie, Rami Kantar, Laura DiChiacchio, Joseph R. Scalea


  • Donor Procurement After Circulatory Death

    by Josue Alvarez-Casas, Maher Sraj, Joseph R. Scalea

  • Open Access

    An Initial Analysis of the Baseline Levels of Dd-cfDNA After Pancreas Transplantation: A Prospective Study From High-volume Centers in the United States

    by Ashley Bs Yoo, Alexandria Bs Riedel, Ian Bs Qian, Amanda Mba Bartosic, Rudi Bs Soltani, Gulam Mbbs Kibria, Abdolreza Haririan, Cinthia B. Drachenberg, Peter L. Abrams, Jon S. Odorico, et al.

    Background.: Pancreas transplantation offers patients with diabetes an opportunity for glucose homeostasis. Current blood tests to surveil for rejection have poor sensitivity and specificity for identifying rejection, and pancreas biopsies are challenging and associated with morbidity and graft loss. Donor-derived cell-free DNA (dd-cfDNA) is shed from transplanted organs and detectable in peripheral blood. Thus, a potential dd-cfDNA blood test assessing rejection would be clinically advantageous. Methods.: One hundred eighty-one dd-cfDNA samples (n) were collected from 77 patients (N) up to 132 mo posttransplant. Results.: The median dd-cfDNA level among all subjects was 0.28% (0.13%, 0.71%). In simultaneous pancreas-kidney (SPK) transplant recipients, the median dd-cfDNA level was 0.29% (0.13%, 0.71%), and it was 0.23% (0.08%, 0.71%) in pancreas transplant alone (PTA) recipients. When isolating for when without infection or rejection, the median dd-cfDNA level was 0.28% (0.13%, 0.64%) for SPK and 0.20% (0.00%, 0.32%) for PTA. Both transplant types approached 1.0% ≤1 mo posttransplant followed by a decrease in median dd-cfDNA. During episodes of rejection or infection, median dd-cfDNA levels were greater among all transplant types. Conclusions.: The mean dd-cfDNA level for all pancreas transplant recipients is 1.0%), regardless of SPK or PTA. Early posttransplant dd-cfDNA levels are transiently higher than later measurements. Dd-cfDNA elevation also correlates with rejection and infection and thus is a promising biomarker for surveilling pancreas transplant dysfunction.


  • Open Access

    Transport-Associated Vibrational Stress Triggers Drug-Reversible Apoptosis and Cardiac Allograft Failure in Mice

    by Young S. Lee, Samuel J. Gavzy, Jihyun Jang, Shani Kamberi, Tianshu Zhang, Lauren Sands, Joseph R. Scalea

    Increasingly complex and long-range donor organ allocation routes coupled with implementation of unmanned aerial vehicles (UAVs) have prompted investigations of the conditions affecting organs once packaged for shipment. Our group has previously demonstrated that different modes of organ transport exert unique environmental stressors, in particular vibration. Using a mouse heart transplant model, we demonstrated that vibrational forces exert tangible, cellular effects in the form of cardiomyocyte apoptosis and cytoskeletal derangement. Functionally, these changes translated into accelerated allograft loss. Notably, administration of an apoptosis inhibitor, Z-VAD-FMK, helped to ameliorate the detrimental cellular and functional effects of mechanical vibration in a dose-dependent manner. These findings constitute one of the first reports of the negative impact of transit environment on transplant outcomes, a contributing mechanism underpinning this effect, and a potential agent to prophylax against this process. Given current limitations in measuring donor organ transit environments in situ , further study is required to better characterize the impact of transport environment and to potentially improve the care of donor organs during shipment.